Atopic Dermatitis

Audrey Dean and her dermatologist, Jennifer Holman, MD, FAAD, discuss the importance of having a network of support when diagnosed with atopic dermatitis.

The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.

Roflumilast maintained disease control when patients switched to twice-weekly dosing.

The review found that utilizing dupilumab to treat these patients with AD cost more than using baricitinib, although dupilumab was more effective.

As we approach National Eczema Week and National Eczema Month, take a look at the most influential atopic dermatitis research from the last decade.

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial symptoms and how the disease impacted her quality of life (QoL). Jennifer Holman reflects on how her practice and approaches have changed as she learned more about the daily impact of atopic dermatitis.

A dermatologist and her patient discuss the pathophysiology and major comorbidities of atopic dermatitis (AD), highlighting the main differences between adult and adolescent AD.

Two poster presentations at this year’s Society for Pediatric Dermatology Meeting delve into the psychological impact of the condition and a new option for management.

Experts discuss the selectivity of Janus Kinase (JAK) inhibitors and considerations when selecting treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the nuances of box warnings and how clinicians should assimilate these risk factors in the treatment of atopic dermatitis (AD).

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.

The post hoc analysis published in JAMA Dermatology studied the safety and efficacy of tralokinumab in adults aged 65 and older.

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Among children and adolescents with atopic dermatitis, higher severity led to more school absences.

The OX40 monoclonal antibody possesses an extended half-life. In a previous study, this half-life exceeded that of the average conventional IgG.

Acne was mild to moderate in severity and successfully managed with topical or oral treatments.

Diego Ruiz Dasilva, MD, FAAD, reviews the unmet needs and barriers in the treatment landscape of atopic dermatitis.

A patient with atopic dermatitis shares the impact of upadacitinib on her daily life, commenting on her mother’s role in her treatment.

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Ruth Ann Vleugels, MD, MPD, MBA, provides important considerations for clinicians when reflecting upon the safety of oral Janus Kinase (JAK) inhibitors and traditional systemic immunosuppressants.

Trinity Flint shares her experience using upadacitinib to treat atopic dermatitis and the impact it has had on her quality of life.

Diego Ruiz Dasilva, MD, FAAD, shares treatment approaches to atopic dermatitis, focusing on medications such as dupilumab and upadacitinib.